| www.bioportfolio.com |
http://www.bioportfolio.com/bulletin_38.htm
May
11th 2004
|
|
|
Lead
Sponsor:
|
|
Biotech
industry expert Dr. Ron Garren analyzes newsworthy events in the medical
marketplace and places them in the context of value to the investor. Through
his website, he distributes frequent email alerts to subscribers. An archive
of past alerts, along with a model portfolio of biotech stocks is also
available.
http://www.biotechinsight.com/ |
|
In
this WEEK's issue we are concentrating on PAIN:
1) Growthink Research's 2004 Healthcare Venture Capital Report
2) Emerging Neuropathic
Pain Therapeutics
3) Rheumatoid
Arthritis
4) Treatment
Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will
Drive Market Opportunities
5) Intelligence and information resources on Pain
6) BioWatch - email news alerts on the
life science industry |
|
Headline Sponsor: |
|
BIOPHARM
EXCHANGE #7 AUCTION. Major Sale of Biotechnology, Pharmaceutical and Lab
Equipment.
Bid online May 25, 6am to 2pm PT, at DoveBid’s website: www.dovebid.com.
Assets located in California and North Carolina.
For more information, visit our website or call 800-665-1042.
|
| Growthink
Research's 2004 Healthcare Venture Capital Report |
|
Growthink
Research’s 2004 Healthcare Venture Capital Report analyzes and profiles
the 470 healthcare companies that raised venture capital in 2003
(representing $5.8 billion) and more than 525 investors that funded them.
All company and investor profiles include complete contact information.
The report is organized
by 4 key sectors:· Biotechnology/Pharmaceutical | Diagnostic/Patient Care |
Healthcare Software & Services | Medical Devices. Pages: 213.
Format: PDF Published: 24th April 2004
The Report provides many benefits to several
audiences:
- Early Stage Ventures: unique insight into
the funding market; identification of the best investors to target;
identification of potential partners; critical competitive intelligence.
- Venture Capitalists: critical competitive
intelligence for decision-making regarding current portfolio and new
investments.
- Mid-Stage and Late-Stage/Fortune 500
Companies: critical competitive intelligence and identification of
potential ventures to invest in, partner with, or acquire.
- Product & Service Providers:
identification of the most promising ventures that could use your
products and services.
http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_Growthink_5.html
|
| Emerging
Neuropathic Pain Therapeutics |
 |
Currently,
neuropathic pain is managed through a combination of anticonvulsants,
opioids, and various antidepressants. Yet, most therapeutics available on
the market are not specifically indicated for neuropathic pain, and exhibit
inadequate efficacy and adverse events profile. Therefore, many
pharmaceutical companies recognize the opportunity to provide better
therapeutics and the subsequent market potential. With promising clinical
trial results, eleven emerging therapeutics will likely gain significant
market share between 2004 and 2009. 161 pp. January 2004.
Price: $3,200.00 Order online:
http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html
|
| Rheumatoid
Arthritis |
|
With
the worldwide prevalence of rheumatoid arthritis (RA) estimated at more than
20 million people in 2004 (based on U.S. Census Bureau data, World Health
Organization statistics, and epidemiology studies), there is increasing
demand for effective therapeutics to improve patient quality of life. At
present, there is no cure for RA. Historically, the goal of treatment has
been to provide pain relief, and slow disease progression. Patients with
joint pain usually try over-the-counter (OTC) painkillers and visit the
doctor only when the pain continues. The first line of treatment for RA is
the use of traditional analgesics while corticosteroids are very effective
in reducing inflammation. Second line treatments include disease-modifying
anti-rheumatoid drugs (DMARDs), such as methotrexate and biological response
modifiers are prescribed for patients experiencing severe RA symptoms who
have not responded to DMARDs. Because multiple classes of medications are
available, it is routine for physicians to make several attempts before
finding the appropriate treatment regimen for each patient. Eight emerging
therapeutics are forecasted to enter this segment between 2004 and 2009. 235
pp. March 2004
Price: $3,200.00 Order online:
http://www.bioportfolio.com/cgi-bin/acatalog/Navigant_Consulting.html
|
| Treatment
Algorithms: Cancer Pain - Physician Awareness and Novel Drug Delivery Will
Drive Market Opportunities |
 |
Cancer
pain can be associated with the cancer itself or with conventional cancer
treatments such as chemotherapy or surgery, and it affects over 3 million
people in the US alone. Currently, there is a vast range of drugs used in
the treatment of cancer pain including opioids, NSAIDs, antidepressants and
anticonvulsants, yet most physicians consider morphine to be the current
gold standard.
- Key data and detailed analysis of the 7
leading pharmaceutical markets: the US, Japan, Germany, France, Italy,
Spain, and the UK
- In-depth analysis of presentation rates,
diagnosis and referral patterns of cancer pain
- Detailed examination of first, second and
third line therapies for the treatment of mild, moderate and severe
cancer pain
- Investigation of the treatment of
breakthrough pain
Report Highlights
Cancer pain affects over three million people
in the US alone, yet despite the availability of a wide range of analgesics
and published treatment guidelines, many patients still receive inadequate
pain management
Increased education and awareness of cancer
pain and its management among physicians and patients is of critical
importance in improving treatment outcomes
Reasons to Purchase
- Identify commercial opportunities from an
understanding of the prevalence of cancer pain in the seven major
pharmaceutical markets
- Exploit the opportunity to play a pivotal
role in promoting effective pain management by providing increased
patient and physician education
- Identify first, second and third-line
preferred therapies for cancer pain, and the novel non-invasive
formulations of breakthrough pain analgesics.
Price $12,800.00 Order online: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a268
|
| Intelligence
and knowledge resources supporting Pain R&D |
| BioPortfolio
offers its readers the opportunity to access a wide range of information
resources on CNS diseases - to evaluate review the links below:
1) Pain R&D News: Back
Pain | Pain
| Palliative
Care Pain | Arthritis
Rheumatoid
2) Pre-defined web
searches covering all Pain conditions: Pain
| Palliative
Care Pain | Back
Pain
3) Therapeutic Advances - Focus
on Pain:
http://www.bioportfolio.com/LeadDiscovery/targetpain.htm
4) Subscribe
to CNS
Diseases DailyUpdate:
http://www.bioportfolio.com/leaddiscovery/daily_update_index.htm
5) Leading CNS Diseases
Companies - Stock prices
http://www.bioportfolio.com/nasdaq/scroll_Neurological.htm
|
| BioWatch
- email news alerts on the life science industry |
|
You
select the topic and we deliver breaking news direct to your email box!
“Sentrx has been a subscriber to BioPortfolio for
more than a year and we are very pleased with the services provided. We
receive news items throughout the day to identify companies that may have a
need for Sentrx drug safety solutions. Using this information, we have
established a direct mail campaign that is proving to be successful at
generating leads. All of our press releases are distributed through
BioPortfolio, and the service reaches a wide audience at a reasonable price.
Any technical issues are quickly resolved in a courteous, professional
manner. I highly recommend BioPortfolio.com.” Jill M. Notte,
Director of Marketing, Sentrx
"We have used the BioPortfolio BioWatch News
email alert service for two years to track commercial developments in
diabetes, oncology and CNS – we will be subscribing for a third year
because we find it a user friendly and an excellent vehicle for keeping us
aware”. Lester Salans.
Download the BioWatch
News Email Alert pdf brochure (100 Kb) (100 Kb) and order form!
Read more at: http://www.bioportfolio.com/news_tracking/index.htm
|
|
|
Contact
us:
Editorial and features: peter.barfoot@bioportfolio.com
Subscriber
information:
To subscribe for the
BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com
To unsubscribe,
email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove your email
address from the list based on your email address. If your email has
changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually unsubscribe for you.
Thank you for your understanding.
©2004
BioPortfolio Limited
|
|
